X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.prnewswire.com/news-releases/alkermes-presents-analyses-from-long-term-safety-study-of-lybalvi-olanzapine-and-samidorphan-at-2024-congress-of-the-schizophrenia-international-research-society-302109802.html
https://www.prnewswire.com/news-releases/alkermes-announces-topline-results-from-long-term-open-label-safety-and-durability-of-treatment-effect-study-of-lybalvi-olanzapine-and-samidorphan-302024987.html
https://www.fiercepharma.com/marketing/alkermes-lybalvi-a-new-litmus-test-for-mental-illness-marketing
https://www.prnewswire.com/news-releases/alkermes-announces-positive-topline-results-from-enlighten-early-phase-3b-study-of-lybalvi-in-patients-early-in-illness-301477193.html
https://www.reuters.com/business/healthcare-pharmaceuticals/alkermes-schizophrenia-drug-gets-us-fda-nod-2021-06-01/
https://www.prnewswire.com/news-releases/fda-accepts-alkermes-resubmission-of-new-drug-application-for-alks-3831-301198736.html
https://www.prnewswire.com/news-releases/journal-of-clinical-psychiatry-publishes-data-from-alkermes-phase-3-enlighten-1-efficacy-study-of-alks-3831-in-patients-with-schizophrenia-301015875.html
https://endpts.com/did-a-disaster-crush-your-stock-in-2018-these-biotechs-were-happy-to-come-up-with-some-rich-compensation-deals-for-the-ceo-anyway/
http://www.pharmatimes.com/news/fda_advisors_turn_down_alkermes_alks_5461_1258394
https://www.prnewswire.com/news-releases/alkermes-announces-publication-of-phase-3-data-for-alks-5461-for-adjunctive-treatment-of-major-depressive-disorder-in-molecular-psychiatry-300739455.html
https://www.prnewswire.com/news-releases/alkermes-announces-publication-of-phase-3-data-for-alks-5461-for-adjunctive-treatment-of-major-depressive-disorder-in-molecular-psychiatry-300739455.html
http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-corporateNewsArticle&ID=2350407
http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-corporateNewsArticle&ID=2340507
Market Place
Share 
